drugset
drugset / Trial / NCT03263507

Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Donidalorsen (IONIS-PKK-LRx) Administered Subcutaneously to Healthy Volunteers

NCT03263507 ↗

Phase 1 Completed 32 enrolled Ionis Pharmaceuticals, Inc.
RandomizedParallel-groupDouble-blindTreatment

Summary

The purpose is to assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Donidalorsen administered subcutaneously to Healthy Volunteers

Timeline

Start
2017-08-28
Primary completion
2018-10-09
Completion
2018-10-09

Drugs

EvaluationDrugModalityDoseRoute
Subject Donidalorsen Antisense oligonucleotide — Subcutaneous

Indications

No indication recorded.